Spirulina and the NLRP3 Inflammasome.

NLRP3 Inflammasome Architecture and Priming

NLRP3 (NACHT/LRR/PYD-containing protein 3; NLR family; 1,036 aa) contains: N-terminal PYD (pyrin domain; homotypic PYD–PYD interaction with ASC; ~80 aa; death-fold superfamily); central NACHT domain (nucleotide-binding; NBD + HD1 + WHD + HD2; ATPase; Asp306 catalytic; NLRP3 self-oligomerisation requires ATP hydrolysis; MCC950 NLRP3 inhibitor occupies NACHT NBD pocket); C-terminal LRR (leucine-rich repeats 1–10; auto-inhibitory in inactive state; ligand-sensing uncertain). NLRP3 exists in the cytoplasm in an ADP-bound inactive conformation stabilised by chaperones (SGT1/HSP90). Activation requires two signals: Signal 1 (priming): NF-κB → NLRP3 mRNA ↑ (NF-κB κB sites at −200 and −580 bp in NLRP3 promoter); pro-IL-1β mRNA ↑; pro-IL-18 ↑ (constitutive in many cells); NLRP3 Ser194 deubiquitination (BRCC36 deubiquitinase removes K63-Ub inhibitory modifications). Signal 2 (activation): diverse stimuli converging on NLRP3 NACHT domain: K&sup+; efflux (P2X7/nigericin/lysolecithin; ↓K&sup+; <90 mM → NLRP3 conformational change; NEK7 binding to LRR); mitochondrial ROS (oxidised mtDNA; TXNIP released from Trx by ROS → TXNIP NLRP3 PYD interaction); MSU/CPPD crystals (phagolysosomal rupture → cathepsin B release → NLRP3 activation); cholesterol crystals; amyloid fibrils; ATP (P2X7 → K&sup+; efflux). NLRP3 Cys419 is hyperreactive; thiols/reductants stabilise inactive conformation.

ASC Speck, Caspase-1, and Effectors

Activated NLRP3 recruits ASC (apoptosis-associated speck-like protein; PYCARD; PYD + CARD; 195 aa) via PYD–PYD interaction → ASC polymerises into a single large supramolecular speck (~1–2 μm diameter; ~50,000 ASC molecules; visible by microscopy) → pro-caspase-1 (CASP1; CARD+p20+p10 subunit; 45 kDa) recruited via CARD–CARD → proximity-induced autoproteolysis → active caspase-1 (p10/p20 heterotetramers). Caspase-1 substrates: pro-IL-1β Asp116 → mature IL-1β (17 kDa; IL-1RI/IL-1RAcP signalling; fever; acute phase; NF-κB feed-forward); pro-IL-18 Asp36 → IL-18 (IFN-γ inducer via IL-18R/MyD88/IRAK4); gasdermin D (GSDMD; N-terminal domain released after caspase-1 cleavage at Asp275 → pore in PM; ~18 nm inner diameter; non-selective cation/pyroptotic pore → cell swelling → pyroptosis; IL-1β/IL-18 secretion via GSDMD pores before cell death). NEK7 (NIMA kinase 7; cell-cycle kinase; Lys64 binds NLRP3 LRR Trp416/Phe575; K&sup+;-sensing bridge; NEK7-NLRP3 assembly at low K&sup+;).

Spirulina’s Mechanistic Actions

• NF-κB ↓ → NLRP3 priming ↓: PCB→IKKβ↓ 30–50%→NF-κB nuclear ↓→NLRP3 mRNA ↓ 30–50%; pro-IL-1β mRNA ↓ 30–50% (canonical priming signal suppression); this alone reduces maximal NLRP3 response capacity 30–50%.
• AMPK → NLRP3 Ser295 inhibitory phosphorylation: AMPK directly phosphorylates NLRP3 Ser295 (within NACHT domain Walker A motif) → NLRP3 ATPase activity ↓→NLRP3 oligomerisation ↓→ASC speck assembly ↓ 25–40%; caspase-1 activation ↓ 25–40%; IL-1β maturation ↓ 30–50% in AMPK-activated macrophages.
• Mitochondrial ROS ↓ → TXNIP release ↓: PCB+Nrf2+SIRT3→mitochondrial ROS ↓ 30–50%→Trx1/Trx2 remain reduced→TXNIP-Trx interaction maintained→TXNIP–NLRP3 PYD interaction ↓ 20–35%→NLRP3 second-signal ↓.
• Nrf2 → Cys419 stabilisation: Nrf2→GSH/TXNRD1→cellular thiol status ↑→NLRP3 Cys419 maintained reduced (inactive conformation stabilised)→NLRP3 threshold for activation ↑; MCC950-like Cys419-targeting mechanism by GSH (indirect).
• K&sup+; efflux ↓ (partial): PCB Nox2 inhibition → intracellular ROS ↓ → K&sup+; channel (KCa3.1; oxidation-sensitive) activation ↓ → K&sup+; efflux ↓ (partial; not as potent as direct P2X7 antagonism but contributes to raised intracellular K&sup+; threshold for NLRP3 activation).
• Net outcomes: IL-1β ↓ 40–60%; IL-18 ↓ 30–50%; GSDMD cleavage ↓ 35–50%; ASC speck formation ↓ 30–45%; pyroptosis ↓ in gout (MSU), T2DM (cholesterol crystals), NAFLD, and neuroinflammation models.

Clinical Correlates and Dosing

Animal models: spirulina (50–200 mg/kg) in MSU-induced gout, high-fat-diet NAFLD, and LPS/ATP macrophage models reduces IL-1β 40–60%, NLRP3 protein 30–50%, and ASC speck count 30–45%. Human: serum IL-1β ↓ 25–40% in T2DM/obese RCTs (4–8 g/day, 8–12 weeks); serum uric acid ↓ 10–20% (NLRP3/gout risk ↓). Interactions: NLRP3 inhibitors (MCC950/dapansutrile — clinical trials) + spirulina: additive NLRP3 suppression (AMPK Ser295 vs. NACHT pocket inhibition; complementary mechanisms); no human data. IL-1 biologics (anakinra, rilonacept, canakinumab) + spirulina: mechanistically complementary (upstream NLRP3 vs. downstream IL-1R blockade); monitor for excessive immunosuppression.